Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1446414
This article is part of the Research Topic The Molecular Mechanism in Anti-tumor Therapy Resistance View all 7 articles

HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future

Provisionally accepted
Luying Xu Luying Xu Yuxin Xie Yuxin Xie *Qiheng Gou Qiheng Gou Rui Cai Rui Cai Rong Bao Rong Bao Yucheng Huang Yucheng Huang Tang Ruisi Tang Ruisi
  • West China Hospital, Sichuan University, Chengdu, China

The final, formatted version of the article will be published soon.

    Breast cancer (BC) has the second highest incidence among cancers and is the leading cause of death among women worldwide. The human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% to 30% of BC patients. The development of HER2-targeted drugs, including monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs), has improved the operation rate and pathological remission rate and reduced the risk of postoperative recurrence for HER2-positive early-stage BC (HER2+ EBC) patients. This review systematically summarizes the mechanisms, resistance, therapeutic modalities and safety of HER2-targeted drugs and helps us further understand these drugs and their use in clinical practice for patients with HER2+ EBC.

    Keywords: HER2-positive breast cancer, early-stage breast cancer, targeted therapy, Neoadjuvant Therapy, adjuvant therapy

    Received: 09 Jun 2024; Accepted: 30 Aug 2024.

    Copyright: © 2024 Xu, Xie, Gou, Cai, Bao, Huang and Ruisi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yuxin Xie, West China Hospital, Sichuan University, Chengdu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.